Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antidepressant + cariprazine
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination therapy consisting of an antidepressant (such as an SSRI, SNRI, or NDRI) and cariprazine. Cariprazine is an atypical antipsychotic that acts as a partial agonist at dopamine D2 and D3 receptors (with higher affinity for D3), a partial agonist at serotonin 5-HT1A receptors, and an antagonist at serotonin 5-HT2A/5-HT2B/5-HT2C, histamine H1, and alpha-1 adrenergic receptors. The combination is used as adjunctive treatment for major depressive disorder (MDD) in adults who have not responded adequately to antidepressant monotherapy. The mechanism involves modulation of dopamine and serotonin neurotransmission to improve mood symptoms when standard antidepressants alone are insufficient[4][6][7][8].
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))SERT (Sodium-dependent serotonin transporter)HRH1 (Histamine H1 Receptor)ADRA1A (α1A)HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)mAChR (Muscarinic acetylcholine receptors)DAT (Dopamine plasma membrane transport protein)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)HTR2C (5-hydroxytryptamine 2C receptor)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on antidepressant + cariprazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antidepressant + cariprazine.